AVA-ACEBUTOLOL TABLET

Krajina: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktívna zložka:

ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE)

Dostupné z:

AVANSTRA INC

ATC kód:

C07AB04

INN (Medzinárodný Name):

ACEBUTOLOL

Dávkovanie:

400MG

Forma lieku:

TABLET

Zloženie:

ACEBUTOLOL (ACEBUTOLOL HYDROCHLORIDE) 400MG

Spôsob podávania:

ORAL

Počet v balení:

100

Typ predpisu:

Prescription

Terapeutické oblasti:

BETA-ADRENERGIC BLOCKING AGENTS

Prehľad produktov:

Active ingredient group (AIG) number: 0131282002; AHFS:

Stav Autorizácia:

CANCELLED POST MARKET

Dátum Autorizácia:

2014-08-21

Súhrn charakteristických

0
PRODUCT MONOGRAPH
AVA-ACEBUTOLOL
ACEBUTOLOL TABLETS (AS HYDROCHLORIDE)
100, 200 AND 400 MG
ANTIHYPERTENSIVE AND ANTI-ANGINAL AGENT
AVANSTRA INC.
DATE OF PREPARATION:
10761 – 25
TH NE, SUITE 110, BUILDING “B”
FEBRUARY 18, 2011
CALGARY, ALBERTA
T2C 3C2
CONTROL #144984
1
PRODUCT MONOGRAPH
AVA-ACEBUTOLOL
Acebutolol Tablets (as Hydrochloride)
100, 200 and 400 mg
THERAPEUTIC CLASSIFICATION
Antihypertensive and Anti-anginal Agent
ACTIONS AND CLINICAL PHARMACOLOGY
Acebutolol is a beta-adrenergic receptor blocking agent. In vitro and
in vivo animal studies have
shown that it has a preferential effect on beta
1
adrenoreceptors, chiefly located in cardiac muscle.
This preferential effect is not absolute, however, and at higher doses
acebutolol also inhibits
beta
2
adrenoreceptors, chiefly located in the bronchial and vascular
musculature. It possesses
some partial agonist activity (or intrinsic sympathomimetic activity -
ISA). It is used in the
treatment of hypertension and/or prophylaxis of angina pectoris.
The mechanism of the antihypertensive effect has not been established.
Among the factors that
may be involved are:
a)
competitive ability to antagonize catecholamine-induced tachycardia at
the beta-receptor
sites in the heart, thus decreasing cardiac output;
b)
inhibition of renin release by the kidneys;
c)
inhibition of the vasomotor centres.
2
The mechanism of the anti-anginal effect is also uncertain. An
important factor may be the
reduction of myocardial oxygen requirements by blocking
catecholamine-induced increases in
heart rate, systolic blood pressure, and the velocity and extent of
myocardial contraction.
Acebutolol hydrochloride is well absorbed from the gastrointestinal
tract. It undergoes extensive
first-pass hepatic biotransformation, with an absolute bioavailability
of approximately 40% for the
parent compound. The major metabolite, an N-acetyl derivative
(diacetolol), is pharmacologically
active. This metabolite is equipotent to acebutolol and, in cats, is
more cardioselective than
acebutolol; the